A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bexicaserin (Primary)
Indications Developmental disabilities; Dravet syndrome; Early infantile epileptic encephalopathy 2; Lennox-Gastaut syndrome; Tuberous sclerosis
Focus Adverse reactions; Therapeutic Use
Sponsors Longboard Pharmaceuticals

Most Recent Events

27 Jan 2025 Status changed from active, no longer recruiting to completed.
04 Dec 2024 Planned End Date changed from 1 Oct 2024 to 1 Dec 2024.
04 Dec 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight